2--c-methylcytidine and phosphoramidic-acid

The first synthesis of 1'-C-CN, 2'-F, 2'-C-Me pyrimidines is described. Anti-HCV activity was assessed and compared to the 1'-C-CN, 2'-C-Me as well as the 2'-F, 2'-C-Me pyrimidines. A phosphoramidate prodrug of the cytidine derivative showed activity in the low micromolar range against HCV replicons.

Topics: Amides; Antiviral Agents; Cell Line; Halogenation; Hepacivirus; Hepatitis C; Humans; Methylation; Phosphoric Acids; Prodrugs; Pyrimidine Nucleosides; Replicon; RNA-Dependent RNA Polymerase

Thirty novel α- and β-d-2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleoside analogs were synthesized and evaluated for in vitro antiviral activity. Several α- and β-7-deazapurine nucleoside analogs exhibited modest anti-HCV activity and cytotoxicity. Four synthesized 7-deazapurine nucleoside phosphoramidate prodrugs (18-21) showed no anti-HCV activity, whereas the nucleoside triphosphates (22-24) demonstrated potent inhibitory effects against both wild-type and S282T mutant HCV polymerases. Cellular pharmacology studies in Huh-7 cells revealed that the 5'-triphosphates were not formed at significant levels from either the nucleoside or the phosphoramidate prodrugs, indicating that insufficient phosphorylation was responsible for the lack of anti-HCV activity. Evaluation of anti-HIV-1 activity revealed that an unusual α-form of 7-carbomethoxyvinyl substituted nucleoside (10) had good anti-HIV-1 activity (EC(50)=0.71±0.25 μM; EC(90)=9.5±3.3 μM) with no observed cytotoxicity up to 100 μM in four different cell lines.

Topics: Amides; Antiviral Agents; Cell Line; Fluorine; Hepacivirus; Humans; Inhibitory Concentration 50; Molecular Structure; Nucleosides; Phosphoric Acids; Prodrugs; Purines; Virus Replication

The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported. 2'-C-Methylcytidine, as its valyl ester prodrug (NM283), was efficacious in reducing the viral load in patients infected with HCV. Several of the phosphoramidates prepared demonstrated a 10- to 200-fold superior potency with respect to the parent nucleoside in the cell-based replicon assay. This is due to higher levels of 2'-C-methylcytidine triphosphate in the cells. These prodrugs are efficiently activated and converted to the triphosphate in hepatocytes of several species. Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides.

Topics: Amides; Animals; Antiviral Agents; Cell Line; Cytidine; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Phosphoric Acids; Polyphosphates; Prodrugs; Structure-Activity Relationship; Virus Replication

A variety of new prodrugs of 2'-methyl cytidine based on acyloxy ethylamino phosphoramidates have been synthesized and tested in vitro and in vivo for their biological activity. Compared with the parent drug a 10- to 20-fold increase in formation of nucleotide triphosphate in rat and human hepatocytes could be achieved.

Topics: Amides; Animals; Cells, Cultured; Cytidine; Dogs; Drug Evaluation, Preclinical; Hepacivirus; Hepatocytes; Humans; Phosphoric Acids; Prodrugs; Rabbits; Rats; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins